| Kim, Tae Won |
NEMO, NCT03128021: Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response |
|
|
| Completed | 4 | 57 | US | Escitalopram Pill, Lexapro, Placebo, Levomilnacipran Pill, Fetzima | Howard Aizenstein, Weill Cornell Institute of Geriatric Psychiatry, National Institute of Mental Health (NIMH) | Major Depressive Disorder | 06/23 | 08/23 | | |
| Recruiting | 4 | 3944 | RoW | aspirin, clopidogrel, prasugrel, ticagrelor | Asan Medical Center | Coronary Artery Disease | 08/27 | 12/28 | | |
NCT06545526: Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis |
|
|
| Recruiting | 3 | 28 | RoW | celecoxib monotherapy, celecoxib and metformin combination | Yonsei University | Familial Adenomatous Polyposis | 06/26 | 06/26 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 2 | 72 | RoW | Niclosamide, placebo | Yonsei University | Familial Adenomatous Polyposis | 12/22 | 02/23 | | |
NCT03435107: Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 33 | RoW | Durvalumab | Asan Medical Center | Metastatic Colorectal Cancer | 04/23 | 04/23 | | |
| Recruiting | 2 | 45 | RoW | Aatezolizumab plus Bevacizumab, Ticentriq plus Avastin | Tae Won Kim | Hepatocellular Carcinoma | 06/26 | 12/26 | | |
SPECTRUM, NCT05253118: Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) |
|
|
| Recruiting | 2 | 28 | RoW | Tislelizumab, BGB-A317, Pemetrexed | Seoul National University Hospital, Gyeongsang National University Hospital, Kyunghee University Medical Center, Inje University Haeundae Paik Hospital, Chungnam National University Hospital | DLBCL | 12/25 | 02/26 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 03/27 | | |
NCT05503797: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations |
|
|
| Recruiting | 2 | 250 | Europe, Canada, US, RoW | Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R) | Fore Biotherapeutics | Cancer Harboring BRAF Alterations | 06/25 | 08/26 | | |
ACE, NCT05741060: Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers |
|
|
| Active, not recruiting | 2 | 372 | US | S-equol, Equelle, Placebo | Akira Sekikawa, National Institute on Aging (NIA) | Arterial Stiffness, White Matter Lesions, Cognitive Decline | 10/26 | 01/27 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
NCT04696848: The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors |
|
|
| Terminated | 1/2 | 25 | RoW | CKD-516 plus Durvalumab, CKD-516 plus MEDI4736 | Tae Won Kim | Colorectal Cancer, Solid Tumor | 03/23 | 03/23 | | |
| Active, not recruiting | 1/2 | 323 | US, RoW | FLX475, pembrolizumab (KEYTRUDA®) | RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Cancer | 09/24 | 01/25 | | |
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 110 | US, RoW | EU101 | Eutilex | Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer | 09/25 | 12/25 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC |
|
|
| Recruiting | 1/2 | 150 | US, RoW | JIN-A02 | J Ints Bio | EGFR Mutant Advanced Non-small Cell Lung Cancer | 07/24 | 11/25 | | |
| Recruiting | 1 | 180 | Europe, US, RoW | IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan | IDEAYA Biosciences | Solid Tumor | 12/26 | 03/27 | | |
NCT03284502: HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 148 | RoW | HM95573, cobimetinib, HM95573, cetuximab | Hanmi Pharmaceutical Company Limited | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 09/24 | 12/24 | | |
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer |
|
|
| Active, not recruiting | 1 | 70 | US, RoW | TORL-2-307-MAB | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/25 | | |
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer |
|
|
| Recruiting | 1 | 70 | US, RoW | TORL-2-307-ADC | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 01/26 | | |
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
| Not yet recruiting | N/A | 103 | RoW | Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks | Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb | Chronic Hepatitis C | 12/18 | 12/22 | | |
| Recruiting | N/A | 180 | RoW | Online real-time quality measurement and feedback video-based CPR training, Online real-time feedback video-based CPR training without quality measurement, Conventional CPR training | Seoul National University Hospital | Cardiopulmonary Resuscitation, Education | 12/21 | 03/22 | | |
NCT04239794: The Influence of Type of Anesthesia on Postoperative Pain |
|
|
| Active, not recruiting | N/A | 468 | RoW | Propofol, Propofol 2%, Sevoflurane, Sevoflurane inhalant product | Seoul National University Hospital | Colo-rectal Cancer, Anesthesia | 12/23 | 01/24 | | |
NCT04203849: Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy |
|
|
| Enrolling by invitation | N/A | 5000 | RoW | | National Cancer Center, Korea | Breast Cancer | 06/22 | 06/34 | | |
NCT05100485: Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108) |
|
|
| Completed | N/A | 1000 | RoW | Esophagogasrtoduodendoscopy, Hepatic venous pressure gradient | Hepatopancreatobiliary Surgery Institute of Gansu Province, Tianjin Second People's Hospital, The Third People's Hospital of Taiyuan, Ehime University Graduate School of Medicine, Korea University Ansan Hospital, Hyogo Medical University, Zagazing University Faculty of Medicine, Institute of Liver and Biliary Sciences (ILBS), Changi General Hospital, Ruijin Hospital | Compensated Advanced Chronic Liver Disease | 01/23 | 01/23 | | |
NCT05559502: High Flow Nasal Oxygenation vs Endotracheal Intubation on Recovery Profiles in Laryngeal Microsurgery |
|
|
| Recruiting | N/A | 52 | RoW | HFNO group, Optiflow, ET group, Portex, Smiths Medical International Ltd., South East England, United Kingdom | Ajou University School of Medicine | Cough | 06/24 | 06/24 | | |
NCT03969823: Whole Genomic Landscape of Advanced EGFR-mutant NSCLC |
|
|
| Active, not recruiting | N/A | 148 | RoW | Tagrisso, Osimertinib | Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center | Locally Advanced or Metastatic NSCLC | 09/25 | 12/25 | | |
NCT06205212: High-flow Nasal Oxygenation During Preoxygenation and Atelectasis |
|
|
| Recruiting | N/A | 92 | RoW | high-flow nasal oxygen, facemask | Seoul National University Hospital, SMG-SNU Boramae Medical Center | Anesthesia, General, Pulmonary Atelectasis | 10/24 | 10/24 | | |
ICARUS, NCT05805280: IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease |
|
|
| Recruiting | N/A | 100 | RoW | intravascular ultrasound-guided group, angiography-guided group | Asan Medical Center | Femoropopliteal Disease | 12/24 | 12/25 | | |
| Recruiting | N/A | 511 | RoW | | Asan Medical Center | Diabetes Mellitus | 12/24 | 12/24 | | |
NCT06216912: Gastric Volume in Paralyzed Obese Patients After High-flow Nasal Oxygen Therapy |
|
|
| Recruiting | N/A | 60 | RoW | | Seoul National University Hospital, SMG-SNU Boramae Medical Center | Undefined | 01/25 | 01/25 | | |
OBE-KMT22-01, NCT06250608: Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients. |
|
|
| Not yet recruiting | N/A | 35 | RoW | Pulse oximeter, NIRSITX | OBELAB, Inc., Helptrial Inc. | Acute Ischemic Stroke Patients | 12/24 | 12/24 | | |
| Completed | N/A | 21 | RoW | | Asan Medical Center, LN Robotics | Percutaneous Coronary Intervention | 03/24 | 04/24 | | |
NCT06441175: Effectiveness of Cricoid Pressure During Videolaryngoscopy Versus Direct Laryngoscopy |
|
|
| Not yet recruiting | N/A | 140 | NA | Intubation device order | Seoul National University Hospital, SMG-SNU Boramae Medical Center | Cricoid Pressure | 07/25 | 07/26 | | |
NCT06076083: Multi-omics Database for Integrative Microbiome Analysis in a Cohort of Korean Patients With Ankylosing Spondylitis |
|
|
| Recruiting | N/A | 600 | RoW | | Tae-Hwan Kim, Kyunghee University Medical Center | Ankylosing Spondylitis | 12/25 | 12/27 | | |
| Active, not recruiting | N/A | 797 | RoW | Propofol, Sevoflurane | Seoul National University Hospital, Korean Society of Anesthesiologists, Bundang Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul St. Mary's Hospital, Seoul National University Boramae Hospital | Cancer of Colon, Anesthesia | 05/28 | 05/28 | | |
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD |
|
|
| Recruiting | N/A | 2400 | RoW | Percutaneous Coronary Intervention | Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd | Coronary Disease | 12/26 | 07/30 | | |
PROVE-DM, NCT05579626: Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus |
|
|
| Recruiting | N/A | 4000 | RoW | high-intensity statin arm, low-intensity statin plus ezetimibe | Seung-Whan Lee, M.D., Ph.D., Yuhan Corporation | Pre Diabetes, ASCVD | 12/27 | 12/27 | | |
NCT04466189: Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy |
|
|
| Enrolling by invitation | N/A | 120 | RoW | | National Cancer Center, Korea | Pancreas Cancer | 08/28 | 08/28 | | |
| Recruiting | N/A | 6000 | RoW | Treatment, Intervention | Asan Medical Center | Aorta Disease, Peripheral Artery Disease | 12/34 | 12/44 | | |
NCT05467930: CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2 |
|
|
| Recruiting | N/A | 1000 | US | Survey, Medical History Review, Sample Collection | Columbia University, Gilead Sciences | COVID-19, SARS CoV 2 Infection | 05/25 | 05/26 | | |
NCT04466124: Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy |
|
|
| Enrolling by invitation | N/A | 500 | RoW | Liver Cancer Patients Treated With Proton Beam Therapy | National Cancer Center, Korea | Liver Cancer | 08/28 | 08/28 | | |
NCT05213962: Local and Regional Radiotherapy for Nipple Sparing Mastectomy With Implant |
|
|
| Enrolling by invitation | N/A | 128 | RoW | | National Cancer Center, Korea | Breast Cancer | 12/28 | 12/28 | | |
| Lee, Jong Mog |
| Recruiting | 4 | 3944 | RoW | aspirin, clopidogrel, prasugrel, ticagrelor | Asan Medical Center | Coronary Artery Disease | 08/27 | 12/28 | | |
NCT04497142: Effect of Perampanel on Peritumoral Hyperexcitability in HGG |
|
|
| Completed | 1/2 | 12 | US | Perampanel, E2007, Fycompa, Standard of Care, Standard treatment (typically the anti-seizure medication levetiracetam) | Dana-Farber Cancer Institute, National Cancer Institute (NCI), Eisai Inc. | Glioma, Malignant, Surgery, Seizures | 05/23 | 05/23 | | |
NCT04409080: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy |
|
|
| Recruiting | 1/2 | 33 | Europe, US, RoW | REGN7257 | Regeneron Pharmaceuticals | Severe Aplastic Anemia (SAA) | 01/26 | 05/26 | | |
| Not yet recruiting | 1 | 10 | US | Cenobamate | Brigham and Women's Hospital | Epilepsy, Neurologic Disorder | 12/24 | 06/25 | | |
ASSURE, NCT03306901: Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | N/A | 240 | RoW | Esophagectomy, 5-fluorouracil, 5-FU, Cisplatin, Radiation therapy | Samsung Medical Center, Ministry of Health & Welfare, Korea | Esophageal Cancer | 12/25 | 12/33 | | |
ICARUS, NCT05805280: IntravasCular Imaging-Guided Versus AngiogRaphy-GUided Drug-Eluting Stent Implantation for Fermoropopliteal Artery Disease |
|
|
| Recruiting | N/A | 100 | RoW | intravascular ultrasound-guided group, angiography-guided group | Asan Medical Center | Femoropopliteal Disease | 12/24 | 12/25 | | |
| Not yet recruiting | N/A | 10 | US | Control subjects | Brigham and Women's Hospital | Epilepsy | 06/27 | 06/27 | | |
| Recruiting | N/A | 1800 | US | Therapeutic Hypothermia | University of Michigan, Johns Hopkins University, Medical University of South Carolina, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) | Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain | 07/28 | 08/28 | | |
| Kim, Moon Soo |
| Active, not recruiting | 3 | 197 | RoW | besifovir 150mg, tenofovir 300mg | IlDong Pharmaceutical Co Ltd | Chronic Hepatitis B | 02/16 | 01/23 | | |
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis |
|
|
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc. | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
NCT05532124: Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups. |
|
|
| Recruiting | 2 | 49 | RoW | LAENNEC (Human Placenta Hydrolysate), normal saline | Green Cross Wellbeing | Chronic Liver Disease | 03/23 | 06/23 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 260 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
SOLAR, NCT05673772: Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 364 | RoW | short-course radiotherapy, mFOLFOX6, Chemoradiotherapy, TME surgery | Kyungpook National University Hospital, National Cancer Center, Korea | Rectal Cancer | 12/24 | 12/29 | | |
| Not yet recruiting | N/A | 103 | RoW | Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks | Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb | Chronic Hepatitis C | 12/18 | 12/22 | | |
| Han, Ji-Youn |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT01470716: Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations |
|
|
| Active, not recruiting | 2 | 26 | RoW | Erlotinib, treatment arm | National Cancer Center, Korea, Hoffmann-La Roche | NSCLC Stage II, NSCLC, Stage IIIA | 12/21 | 06/22 | | |
| Active, not recruiting | 2 | 128 | RoW | Erlotinib plus Bevacizumab, Tarceva plus Avastin, Erlotinib, Tarceva | National Cancer Center, Korea, Roche Korea co.,Ltd. | EGFR Positive Non-small Cell Lung Cancer | 12/21 | 07/23 | | |
NCT03808480: Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% |
|
|
| Recruiting | 2 | 22 | RoW | CA and Nivolumab, Opdivo | National Cancer Center, Korea | Non-small Cell Lung Cancer | 05/22 | 05/22 | | |
NCT01441349: Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 192 | RoW | IP chemotherapy, IP, IP chemotherapy plus simvastatin, IPSimva | National Cancer Center, Korea | Small Cell Lung Carcinoma | 10/22 | 12/22 | | |
| Recruiting | 2 | 35 | RoW | Lorlatinib | National Cancer Center, Korea | Nonsmall Cell Lung Cancer | 12/22 | 12/23 | | |
NCT03262454: Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC |
|
|
| Recruiting | 2 | 35 | RoW | Atezolizumab, Tecentriq | National Cancer Center, Korea, Roche Korea co.,Ltd. | Small Cell Lung Cancer Recurrent | 02/23 | 07/24 | | |
NCT04074993: Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays |
|
|
| Active, not recruiting | 2 | 35 | RoW | Brigatinib | JI-YOUN HAN, Seoul National University Hospital, Severance Hospital, Seoul National University Bundang Hospital | Non Small Cell Lung Cancer | 01/25 | 03/25 | | |
NCT05541822: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation |
|
|
| Recruiting | 2 | 40 | US, RoW | ABN401 | Abion Inc | Advanced Solid Tumors | 04/25 | 08/25 | | |
STEREO, NCT04908956: Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC |
|
|
| Terminated | 2 | 6 | Europe, RoW | Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT) | ETOP IBCSG Partners Foundation, AstraZeneca | NSCLC Stage IV, EGFR Gene Mutation | 10/23 | 02/24 | | |
| Active, not recruiting | 1/2 | 856 | Europe, Canada, Japan, US, RoW | LOXO-292, Selpercatinib, LY3527723 | Loxo Oncology, Inc., Eli Lilly and Company | Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor | 02/25 | 02/26 | | |
|
|
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
NCT04052971: To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation |
|
|
| Recruiting | 1 | 78 | RoW | ABN401- Escalation Phase, ABN401- Expansion Phase | Abion Inc, Novotech (Australia) Pty Limited | Advanced Solid Tumors | 12/24 | 12/24 | | |
| Recruiting | 1 | 180 | Europe, US, RoW | IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan | IDEAYA Biosciences | Solid Tumor | 12/26 | 03/27 | | |
| Kim, Min Chan |
NCT05664555: Dose Optimization for Safe and Efficient Fluorescein Angiography (DOSE Study) |
|
|
| Completed | 4 | 144 | RoW | Fluorescein Sodium | Seoul National University Bundang Hospital | Retinal Disease | 03/24 | 03/24 | | |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Active, not recruiting | 3 | 502 | Europe, Canada, Japan, US, RoW | tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Seagen Inc., Genmab | Cervical Cancer | 07/23 | 08/25 | | |
| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
|
|
| Recruiting | 3 | 450 | Europe, Canada, US, RoW | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat | NRG Oncology, National Cancer Institute (NCI) | Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8 | 02/27 | 02/28 | | |
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL |
|
|
| Recruiting | 3 | 504 | Europe, US, RoW | Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone | Acrotech Biopharma Inc. | Peripheral T Cell Lymphoma | 07/30 | 11/30 | | |
NCT04696120: Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial |
|
|
| Not yet recruiting | 2 | 200 | RoW | Apixaban, apixaban 5mg or 2.5mg bid, Placebo, placebo bid | Korea University Guro Hospital, Dt&Sanomedics | Heart Failure, Sinus Rhythm, Cerebrovascular Disease | 08/22 | 02/23 | | |
NCT05665023: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma |
|
|
| Recruiting | 2 | 37 | RoW | Bevacizumab + modified FOLFIRINOX | Yonsei University | Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 02/24 | 02/25 | | |
NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 134 | US, RoW | SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo | Coherus Biosciences, Inc. | Hepatocellular Carcinoma | 05/25 | 05/26 | | |
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 110 | US, RoW | EU101 | Eutilex | Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer | 09/25 | 12/25 | | |
| Recruiting | 1/2 | 220 | Europe, Canada, US, RoW | BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation) | Bold Therapeutics, Inc. | Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma | 06/26 | 09/26 | | |
NCT05113693: Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 |
|
|
| Completed | 1 | 33 | RoW | CKD-393, CKD-501, D759, H053 | Chong Kun Dang Pharmaceutical | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT05113849: Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19) |
|
|
| Recruiting | 1 | 40 | RoW | IN-B009 (Low-dose), IN-B009 (High-dose) | HK inno.N Corporation | COVID-19 | 02/23 | 02/23 | | |
EARLY-UNLOAD, NCT04775472: Early Left Atrial Septostomy Versus Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation |
|
|
| Completed | N/A | 116 | RoW | Early left atrial septostomy within 12 hours after VA-ECMO implantation, Selective left atrial septostomy | Chonnam National University Hospital | Cardiogenic Shock | 03/22 | 10/23 | | |
| Completed | N/A | 70 | US | Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools., SPiN Thoracic Navigation System™, Veran System | Veran Medical Technologies | Lung Lesion(s) Requiring Evaluation, Pulmonary Metastasis, Pulmonary Nodule, Solitary, Peripheral Lung Lesions | 01/23 | 02/23 | | |
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma |
|
|
| Completed | N/A | 203 | RoW | | Boryung Pharmaceutical Co., Ltd | Multiple Myeloma | 01/23 | 01/23 | | |
NCT04853563: Comparison of PEEP in Acute Decompensated Heart Failure |
|
|
| Recruiting | N/A | 120 | RoW | PEEP | Asan Medical Center | Heart Decompensation, Mechanical Ventilation Pressure High | 07/23 | 04/24 | | |
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer |
|
|
| Available | N/A | | Europe, Canada, RoW | Abemaciclib, LY2835219 | Eli Lilly and Company | Metastatic Breast Cancer | | | | |
| Recruiting | N/A | 280 | RoW | Vi-Sealer, Ligasure, Other AHD | Hyun Park | Benign Gynecologic Neoplasm | 12/24 | 10/25 | | |
NCT04322851: B-line by Lung US in Patients With Acute Decompensated Heart Failure |
|
|
| Recruiting | N/A | 300 | RoW | Lung ultrasound | Asan Medical Center | Heart Failure | 03/24 | 03/24 | | |
FRAME-AMI3, NCT06227754: OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts |
|
|
| Recruiting | N/A | 1500 | RoW | Angiography-guided PCI group, Optical coherence tomography-guided PCI group | Chonnam National University Hospital, Samsung Medical Center | ST Elevation Myocardial Infarction, Myocardial Infarction | 12/28 | 12/29 | | |
ORIGO, NCT06597175: Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy |
|
|
| Recruiting | N/A | 300 | RoW | ORIGO | Olive Healthcare | Breast Cancer, Breast Tumor, Mammary Carcinoma, Human | 10/24 | 10/24 | | |
NCT06537752: A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients |
|
|
| Recruiting | N/A | 1052 | RoW | | Boryung Pharmaceutical Co., Ltd | Breast Cancer | 10/26 | 10/26 | | |
| Terminated | N/A | 316 | RoW | Immediate coronary angiography within 2 hours after randomization, Delayed coronary angiography after stabilization of heart failure | Chonnam National University Hospital | Heart Failure, Acute Coronary Syndrome | 03/24 | 03/24 | | |
